73 related articles for article (PubMed ID: 36969030)
1. Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors.
Bang AS; Fay CJ; LeBoeuf NR; Etaee F; Leventhal JS; Sibaud V; Arbesman J; Wang JY; Kwong BY
Breast Cancer Res Treat; 2024 Apr; 204(3):643-647. PubMed ID: 38224427
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force "Dermatology for Cancer Patients" International Study.
Sollena P; Vasiliki N; Kotteas E; Stratigos AJ; Fattore D; Orlandi A; Mannino M; Di Pumpo M; Fida M; Starace M; Apalla Z; Romano MC; Riganti J; Segura S; Martinez AF; Fabbrocini G; Sibaud V; Peris K; On Behalf Of The Eadv Task Force Dermatology For Cancer Patients
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509319
[TBL] [Abstract][Full Text] [Related]
3. Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response.
Pasqualoni M; Orlandi A; Palazzo A; Garufi G; Cannizzaro MC; Pontolillo L; Pannunzio S; Cutigni C; Sollena P; Federico F; Bria E; Tortora G
Front Oncol; 2023; 13():1067264. PubMed ID: 36969030
[TBL] [Abstract][Full Text] [Related]
4. Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review.
Sharaf B; AlMasri R; Abdel-Razeq N; Salama O; Hamad I; Abunasser M; Abdel-Razeq H
Clin Cosmet Investig Dermatol; 2022; 15():5-10. PubMed ID: 35023941
[TBL] [Abstract][Full Text] [Related]
5. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
6. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
[TBL] [Abstract][Full Text] [Related]
8. Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer.
Türkel A; Karaçin C; Öner İ; Şeyran E; Öksüzoğlu B
J Oncol Pharm Pract; 2023 Feb; ():10781552231156521. PubMed ID: 36760158
[TBL] [Abstract][Full Text] [Related]
9. Breast Cancer Statistics, 2022.
Giaquinto AN; Sung H; Miller KD; Kramer JL; Newman LA; Minihan A; Jemal A; Siegel RL
CA Cancer J Clin; 2022 Nov; 72(6):524-541. PubMed ID: 36190501
[TBL] [Abstract][Full Text] [Related]
10. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System.
Raschi E; Fusaroli M; La Placa M; Ardizzoni A; Zamagni C; Poluzzi E; De Ponti F
Am J Clin Dermatol; 2022 Mar; 23(2):247-255. PubMed ID: 34699032
[TBL] [Abstract][Full Text] [Related]
11. Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion.
Lommerts JE; Bekkenk MW; Luiten RM
Expert Opin Drug Saf; 2021 Aug; 20(8):883-888. PubMed ID: 33896329
[No Abstract] [Full Text] [Related]
12. Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.
Sollena P; Nikolaou V; Soupos N; Kotteas E; Voudouri D; Stratigos AJ; Fattore D; Annunziata MC; Orlandi A; Di Nardo L; Apalla Z; Deilhes F; Romano MC; Fabbrocini G; Sibaud V; Peris K;
Breast Cancer Res Treat; 2021 Jan; 185(1):247-253. PubMed ID: 32914354
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study.
Suh Oh HJ; Flórez Menéndez Á; Sacristán Santos V; Fernández Ribeiro F; Vilanova-Trillo L; Constenla Figueiras M; Pereiro Ferreiros M
Drugs Context; 2020; 9():. PubMed ID: 32821263
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]